Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies

Non-small cell lung cancer (NSCLC) remains a cause of significant morbidity and mortality, despite significant advances made in its treatment using immune checkpoint inhibitors (ICIs) over the last decade; while a minority experience prolonged responses with ICIs, benefit is limited for most patient...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-09, Vol.15 (19), p.4797
Main Authors: Gray, Simon, Ottensmeier, Christian H
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Cancer
Cancer therapies
Cells
Chemotherapy
Clinical medicine
Cytokines
Cytotoxicity
Deoxyribonucleic acid
DNA
Geospatial data
Immune checkpoint inhibitors
Immune system
Ligands
Lung cancer
Lung cancer, Non-small cell
Lung cancer, Small cell
Medical prognosis
Metastasis
Monoclonal antibodies
Morbidity
Non-small cell lung carcinoma
Oncology, Experimental
Proteins
Review
Small cell lung carcinoma
Tumor microenvironment
Tumor necrosis factor-TNF
Tumors
Viral antibodies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non-small cell lung cancer (NSCLC) remains a cause of significant morbidity and mortality, despite significant advances made in its treatment using immune checkpoint inhibitors (ICIs) over the last decade; while a minority experience prolonged responses with ICIs, benefit is limited for most patients. The development of multiplexed antibody-based (MAB) spatial tissue imaging technologies has revolutionised analysis of the tumour microenvironment (TME), enabling identification of a wide range of cell types and subtypes, and analysis of the spatial relationships and interactions between them. Such study has the potential to translate into a greater understanding of treatment susceptibility and resistance, factors influencing prognosis and recurrence risk, and identification of novel therapeutic approaches and rational treatment combinations to improve patient outcomes in the clinic. Herein we review studies that have leveraged MAB technologies to deliver novel insights into the TME of NSCLC.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15194797